Referring to the development of drugs for metabolic diseases such as diabetes, Eli Lilly reached a cooperation of more than 700 million US dollars

Continued innovation in diabetes and metabolic diseases has been Lilly's top priority
for many years.
Referring to the development of drugs for metabolic diseases such as diabetes, Eli Lilly recently bet on GPCR to achieve a cooperation
of more than $700 million.
It is reported that Eli Lilly recently reached a cooperation agreement with Sosei Heptares with a total value of $730 million, and Lilly will pay Sosei Heptares an advance payment of $37 million, which may also obtain development and commercialization milestones of up to $694 million, as well as tiered royalties
for global sales 。 Through this collaboration, Eli Lilly will leverage Sosei's StaR platform to design GPCRs with a small number of single-point mutations, and leverage Lilly's expertise in diabetes and metabolic diseases to develop and commercialize small molecule drugs targeting G protein-coupled receptor (GPCR) targets for the treatment of diabetes and metabolic diseases
.
Sosei Heptares is a company
dedicated to developing innovative therapies for GPCRs.
The company's technology platform includes a stable GPCR technology platform
called StaR.
This platform improves the thermal stability of GPCRs by introducing point mutations in GPCRs, so that they maintain stable conformation and original function
even when they are separated from the cell membrane environment.
Sosei Heptares pointed out that GPCRs are an important target type for the treatment of diseases, with nearly 400 GPCRs associated with different diseases, and 34% of new FDA-approved drugs targeting GPCRs
.
However, 56% of GPCR targets remain untargeted, and there are still many opportunities
in this area to develop potential "first-in-class" and "best-in-class" therapies.
Previously, Sosei Heptares also partnered
with pharmaceutical companies such as AbbVie, AstraZeneca, Roche, GlaxoSmithKline, Novartis and Pfizer.
It is understood that Eli Lilly is strong in the field of diabetes, and from the performance alone, diabetes is an important business for Lilly, contributing US$6.
826 billion in revenue in
the first half of 2022.
In the long run, the growth of the company's diabetes business is far from over, the two blockbuster hypoglycemic drugs of dulaglutide and empagliflozin are still strong, and the GIP/GLP-1 dual receptor agonist tirzepatide is poised to take off
.
Eli Lilly said that continuous innovation in diabetes and metabolic diseases has been Lilly's top priority for many years, and looks forward to working with Sosei Heptares and believes that this new partnership can unlock new targets, provide new treatments for these diseases, and bring new treatments
to patients 。 It is understood that recently, Eli Lilly (LLY.
US) also announced a partnership with EVA Pharma to provide sustainable, high-quality, affordable human insulin and analogues
to at least 1 million people with type 1 and type 2 diabetes in low- and middle-income countries, mostly in Africa.
Eli Lilly said this is the first time the company has supplied EVA Pharma with insulin active pharmaceutical ingredients (APIs)
at significantly reduced prices.
Eli Lilly will also provide pro bono technology transfer that will enable EVA Pharma to prepare, fill and complete insulin bottles and cartridges, making the company a trusted producer
of these drugs in Africa.
It is reported that in addition to the field of diabetes, Eli Lilly is involved
in the field of tumors, self-immunity, and neurological diseases.
According to data, Eli Lilly's 2023 revenue will be $30.
3 billion to $30.
8 billion, with earnings per share of $7.
65-7.
85 and adjusted earnings per share of $8.
10-$8.
30
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.